Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Recce Pharmaceuticals
(OP:
RECEF
)
0.2200
UNCHANGED
Last Price
Updated: 9:33 AM EDT, Jun 24, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.2200
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.2200
Today's Range
0.2200 - 0.2200
52wk Range
0.2200 - 0.6000
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial
May 16, 2024
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) managing director and CEO James Graham talks with Proactive’s Jonathan Jackson about how Recce has administered the first doses in the latest cohort of...
Via
TheNewswire.com
Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial
May 16, 2024
Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial
Via
News Direct
Performance
YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
N/A
N/A
1 Year
-63.3%
-63.3%
More News
Read More
Recce Pharma welcomes approval for faster RECCE327 infusion rate
October 26, 2023
Via
News Direct
Recce Pharma welcomes approval for faster RECCE327 infusion rate
October 26, 2023
Via
TheNewswire.com
Recce Pharma says commercial potential of its anti-infectives is gaining recognition
October 11, 2023
Via
TheNewswire.com
Recce Pharma says commercial potential of its anti-infectives is gaining recognition
October 11, 2023
Via
News Direct
Recce Pharma begins dosing in diabetic foot infection trial
August 23, 2023
Via
TheNewswire.com
Recce Pharma begins dosing in diabetic foot infection trial
August 23, 2023
Via
News Direct
Recce Pharmaceuticals provides new hope in fight against superbugs
August 10, 2023
Via
News Direct
Recce Pharmaceuticals provides new hope in fight against superbugs
August 10, 2023
Via
TheNewswire.com
Frequently Asked Questions
Is Recce Pharmaceuticals publicly traded?
Yes, Recce Pharmaceuticals is publicly traded.
What exchange does Recce Pharmaceuticals trade on?
Recce Pharmaceuticals trades on the OTC Traded
What is the ticker symbol for Recce Pharmaceuticals?
The ticker symbol for Recce Pharmaceuticals is RECEF on the OTC Traded
What is the current price of Recce Pharmaceuticals?
The current price of Recce Pharmaceuticals is 0.2200
When was Recce Pharmaceuticals last traded?
The last trade of Recce Pharmaceuticals was at 06/24/25 09:33 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today